Health and Fitness Health and Fitness
Tue, November 2, 2010
[ Tue, Nov 02nd 2010 ] - Market Wire
Coventry Health Care, Expeditors International, A .. source Bergen, Principal Financial and Kellogga?s
[ Tue, Nov 02nd 2010 ] - Market Wire
Neurocrine Biosciences, Jacobs Engineering, Ford, Kellogg and Honda Motor Co.
[ Tue, Nov 02nd 2010 ] - Market Wire
DUSA Pharmaceuticals, Inc.® to Host Third Quarte .. Highlights and Financial Results Conference Call
Mon, November 1, 2010
[ Mon, Nov 01st 2010 ] - Market Wire
Prestige Brands Holdings, Inc. Completes Purchase of Blacksmith Brands
[ Mon, Nov 01st 2010 ] - Market Wire
Biomagnetics Completes Audit and Financial Review
[ Mon, Nov 01st 2010 ] - Market Wire
Oncolytics Biotech(R) Inc. Collaborators to Prese .. t Reovirus Research at the EORTC-NCI-AACR Meeting
[ Mon, Nov 01st 2010 ] - Market Wire
NeoStem to Present at Cell Therapy Industry Summi .. eld on November 3-5, 2010 in Carlsbad, California
[ Mon, Nov 01st 2010 ] - Market Wire
Clinical Data, Inc. Granted Orphan Drug Designati .. for PRX-8066 for Pulmonary Arterial Hypertension
[ Mon, Nov 01st 2010 ] - Market Wire
Gileada?s onderzoeksverbindingen GS 9190 en GS 92 .. erking met standaard zorgtherapien bereiken subst
[ Mon, Nov 01st 2010 ] - Market Wire
Inhibitex Initiates Phase 1b Multiple Ascending D .. l of INX-189 in Patients with Chronic Hepatitis C
[ Mon, Nov 01st 2010 ] - Market Wire
American Anesthesiology Announces the Acquisition of Greensboro, NC, Group Practice
[ Mon, Nov 01st 2010 ] - Market Wire
Hepatitis-C-Prfprparate GS 9190 und GS 9256 von G .. Phase II zusammen mit Standardtherapien wesentli
[ Mon, Nov 01st 2010 ] - Market Wire
ARIAD to Webcast Conference Call on Third Quarter 2010 Financial Results
[ Mon, Nov 01st 2010 ] - Market Wire
Orthovita to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
[ Mon, Nov 01st 2010 ] - Market Wire
Theragenics to Report Third Quarter 2010 Financial Results Tuesday, November 9
[ Mon, Nov 01st 2010 ] - Market Wire
I composti sperimentali per l'epatite C di Gilead .. azione con terapie standard di cura ottengono una
[ Mon, Nov 01st 2010 ] - Market Wire
Two Directors Step Down from Elan Board in Accordance with Previously Announced Intention
[ Mon, Nov 01st 2010 ] - Market Wire
Health Management Associates, Inc. to Present at the Oppenheimer 21st Annual Healthcare Conference
[ Mon, Nov 01st 2010 ] - Market Wire
Porex Corporation Divests Surgical Division to Stryker Corporation
[ Mon, Nov 01st 2010 ] - Market Wire
Medisafe 1 Technologies Appoints Tali Skoczylas as Chair of Medical Advisory Board
Sat, October 30, 2010
[ Sat, Oct 30th 2010 ] - Market Wire
A Celgene anuncia resultados financeiros e operacionais recordes no terceiro trimestre de 2010
[ Sat, Oct 30th 2010 ] - Market Wire
Viread® for Hepatitis B Maintains Antiviral Supp .. ent of Resistance Through Four Years of Treatment
[ Sat, Oct 30th 2010 ] - Market Wire
New Data From Phase 3 Studies Showed Superior SVR .. with Telaprevir-Based Combination Therapy in Peop
[ Sat, Oct 30th 2010 ] - Market Wire
Salix Pharmaceuticals Previews Data Slated for Pr .. ting of the American Association for the Study of
[ Sat, Oct 30th 2010 ] - Market Wire
Gileada?s Investigational Hepatitis C Compounds G .. tion with Standard of Care Therapies Achieve Subs
Fri, October 29, 2010
[ Fri, Oct 29th 2010 ] - Market Wire
Angiotech Pharmaceuticals, Inc. Announces a Stron .. eement with Majority of Senior Subordinated Noteh
[ Fri, Oct 29th 2010 ] - Market Wire
Angiotech Pharmaceuticals, Inc. Releases Selected Projected Financial Information
[ Fri, Oct 29th 2010 ] - Market Wire
Forest Announces FDA Approval of Teflaroa" (cefta .. ment of Community-Acquired Bacterial Pneumonia an
[ Fri, Oct 29th 2010 ] - Market Wire
FDA Classifies Previous Field Action of Medtronic Surgical Device as Class I Recall
[ Fri, Oct 29th 2010 ] - Market Wire
Inhibitex to Present at Two Upcoming Investor Conferences

Inhibitex to Present at Two Upcoming Investor Conferences


Published on 2010-10-29 13:35:50 - Market Wire
  Print publication without navigation


ATLANTA--([ BUSINESS WIRE ])--Inhibitex, Inc. (NASDAQ:INHX), a biopharmaceutical company focused on developing products to treat and prevent serious infectious diseases, announced that Russell H. Plumb, President and Chief Executive Officer, is scheduled to present an overview of the company and its pipeline of differentiated antiviral compounds at the following two investor conferences in November:

  • The Oppenheimer 21st Annual Healthcare Conference on November 3, 2010 at 1:35 PM ET. The conference is being held at the Waldorf-Astoria in New York City.
  • Lazard Capital Markets 7th Annual Healthcare Conference on November 17, 2010 at 10:00 AM ET. The conference is being held at the St. Regis Hotel in New York City.

About Inhibitex

Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a biopharmaceutical company focused on developing products to prevent and treat serious infectious diseases. The Companya™s pipeline includes FV-100, which is in Phase II clinical development for the treatment of shingles, and INX-189, a nucleotide polymerase inhibitor in Phase 1 clinical development for the treatment of chronic hepatitis C infections. The Company also has additional HCV nucleotide polymerase inhibitors in preclinical development, and has licensed the use of its proprietary MSCRAMM® protein platform to Pfizer for the development of staphylococcal vaccines. For additional information about the Company, please visit [ www.inhibitex.com ].

Inhibitex® and MSCRAMM® are registered trademarks of Inhibitex, Inc.

Contributing Sources